Immuneering Appoints Michael Bookman as General Counsel and Secretary
July 20 2021 - 6:47AM
Immuneering Corporation (“Immuneering”), a private
biopharmaceutical company advancing a robust pipeline of oncology
and neuroscience drug candidates that are designed to uniquely
disrupt cellular signaling dynamics, today announced the
appointment of Michael Bookman to the newly created position of
General Counsel and Secretary, effective immediately. Mr. Bookman
will be a member of the Executive Management team and will be
responsible for legal strategy, legal compliance, litigation, and
regulatory matters. In his roles, he will support Immuneering's
Board of Directors in developing and maintaining best practices in
governance policies and procedures.
“Mike is an accomplished biotechnology executive
and lawyer with both in-house and prominent law firm experience. We
are delighted to welcome him to the Immuneering team,” stated Ben
Zeskind, Ph.D., Co-Founder and Chief Executive Officer of
Immuneering. “We look forward to leveraging Mike’s insight,
experience and industry knowledge as we guide Immuneering’s growth
and advance our pipeline of novel product candidates that utilize
bioinformatics and computational biology in creative ways to
potentially bring new medicines to patients who need them the
most.”
“This is an exciting time to be joining
Immuneering as they transition from preclinical development into
human clinical development and leverage their unique ability to
modulate cell signaling dynamics in a variety of indications with
unmet medical needs. I look forward to working with this dynamic
management team to build Immuneering into a leading
biopharmaceutical company,” said Mr. Bookman.
Mr. Bookman joins Immuneering from Frequency
Therapeutics (“Frequency”), where he served as General Counsel and
Secretary since 2019. In this role, he was a member of the
Executive Leadership Team and established and led Frequency’s Legal
Department as its first in-house attorney. Mr. Bookman also played
a key role in Frequency’s initial public offering in October 2019.
Prior to his time at Frequency, Michael was an associate at Latham
& Watkins LLP, a leading international law firm where he worked
on corporate transactional, securities and general business and
governance matters, with an emphasis on representing high-growth
technology and life sciences companies.
Mr. Bookman earned a Bachelor of Business
Administration in Finance, summa cum laude from the University of
Miami and earned his Juris Doctor with a concentration in Law and
Business from the University of Virginia School of Law.
About Immuneering
Corporation
Immuneering is a biopharmaceutical company with
an emerging pipeline focused on improving patient outcomes across a
spectrum of debilitating oncologic and neurologic diseases by
applying its deep knowledge of translational bioinformatics to
every stage of the drug development process. Immuneering has more
than a decade of experience in translational bioinformatics and
generating insights into drug mechanisms of action and patient
treatment responses. Building on this experience, Immuneering has
developed a disease-agnostic platform that enables the company to
utilize human data, novel biology and chemistry, and translational
planning to create and advance its wholly owned pipeline.
Immuneering’s current development programs in oncology are focused
on providing potential treatments for patients with solid tumors
caused by mutations of oncologic signaling pathways, including the
MAPK pathway. Immuneering’s lead product candidate, IMM-1-104, is
designed to be a highly selective dual-MEK inhibitor that further
disrupts KSR for the treatment of advanced solid tumors in patients
harboring RAS mutant tumors. Additionally, Immuneering has six
other oncology programs in the discovery stage that are designed to
target either the MAPK or mTOR pathway, and two neuroscience
programs in the discovery
stage.
Corporate Contact:Rebecca Kusko,
Ph.D.Immuneering Corporation617-500-8080rkusko@immuneering.com
Investor Contact:Anne Marie FieldsManaging
DirectorRx Communications afields@rxir.com
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Immuneering (NASDAQ:IMRX)
Historical Stock Chart
From Jul 2023 to Jul 2024